Skip to main content
. Author manuscript; available in PMC: 2022 Nov 8.
Published in final edited form as: Cancer Cell. 2021 Oct 21;39(11):1519–1530.e4. doi: 10.1016/j.ccell.2021.09.012

Figure 5.

Figure 5.

MRD detectability stratifies patients by risk of progression. (A-D) Progression-free survival (PFS) for patients from the longitudinal cohort stratified by MRD at baseline, post-radiotherapy (RT), mid-chemotherapy, and end-of-therapy. (E-H) PFS for patients from the longitudinal cohort stratified by MRD and clinical risk group at the respective time-points. See also Figures S3 and S4. AR, average-risk; CI, confidence interval; HR, high-risk; neg, negative; pos, positive.